Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 121

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 121
---
,021,696, representing approximately 100% and 78.3% of its total revenues in 2024 and 2023, respectively.

IVF treatment involves the
performance of a series of medical treatment and procedures and eventually brings benefits to clients when embryo is successfully implanted.
Revenue from IVF treatment is recognized at a point in time when different treatment and/or procedure completed in clinic. The completion
of the respective treatments and/or procedures are evidenced by treatment cards and reports maintained in the patient files indicating
successful completion of respective promised obligations.

Surrogacy and ancillary caring services

NewGenIvf also generated
revenue of US$1,114,457 from surrogacy and related ancillary caring services, approximately 21.7% of its total revenue in 2023, provided
at facilities that NewGenIvf operated in Kyrgyzstan. In 2024, due to the reorganization of the Kyrgyzstan operations, NewGenIvf did not
generate any revenue from surrogacy and related ancillary caring services.

In surrogacy and ancillary
caring services, embryo from intending parents is implanted in the surrogate mother sub-contracted by NewGenIvf. During the pregnancy
period of the surrogate mother, NewGenIvf provides ancillary caring services including maternity caring services such as regular body
check and provision of vitamins, supplements and medicines to surrogate mothers, documentation service, and hotel accommodation services.
Revenue from surrogacy and ancillary caring services is recognized at a point in time when the surrogate mother gives birth.

Cost of revenue

The following table sets
forth NewGenIvf’s cost of revenue for the periods indicated.

|                  |     | For the Six Months Ended 
                 June 30, |           |     |      |           |
|                  |     |                     2025 |           |     | 2024 |           |
|                  |     |                      US$ |           |     |  US$ |           |
| Cost of revenues |     |                          | 1,705,824 |     |      | 2,047,970 |

The following table sets
forth a breakdown of NewGenIvf’s cost of revenue by the nature of the cost, in absolute amounts and as percentages of total cost
of revenues, for the periods indicated.

|                        |     | For the Year ended December 31, |      2024 |     |   |       |     |     |      2023 |     |